PlainPharmaWatch

CMS Open Payments · Tool

Integra LifeSciences Corporation vs MIMEDX Group, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

MIMEDX Group, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 364, versus 61 for the other company. Its single largest recorded recipient represents 0.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Integra LifeSciences Corporation
HHI 61 · top recipient 0.0%
Ranked #1,746 of 1,838 companies by HHI
MIMEDX Group, Inc.
HHI 364 · top recipient 0.1%
Ranked #1,404 of 1,838 companies by HHI

Payment Overview

Total Payments
$3.4M
% of Industry
0.0%
Transactions
18,806
Avg per Transaction
$180.65
Recipients
18,727
Avg per Recipient
$181.42
Payment Types
7
Top Payment Type
Consulting Fee
Company B

MIMEDX Group, Inc.

Total Payments
$3.4M
% of Industry
0.0%
Transactions
12,164
Avg per Transaction
$276.92
Recipients
12,157
Avg per Recipient
$277.08
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Integra LifeSciences Corporation vs MIMEDX Group, Inc. - total reported payments in CMS Open Payments PY2024

Integra LifeSciences Corpor…$3.4MMIMEDX Group, Inc.$3.4M

Payment Types Breakdown

Integra LifeSciences Corporation

Consulting Fee $1.1M

32.8%

Food and Beverage $883.9K

26.0%

Travel and Lodging $483.2K

14.2%

Long-Term Medical Supply or Device Loan $363.3K

10.7%

Grant $163.0K

4.8%

Royalty or License $19.3K

0.6%

MIMEDX Group, Inc.

Consulting Fee $1.6M

48.5%

Compensation for Services Other Than Consulting $1.1M

34.1%

Food and Beverage $396.8K

11.8%

Travel and Lodging $144.8K

4.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Integra LifeSciences Corporation

  1. 1

    IAN L VALERIO

    $92,759.48 · 54 txns

  2. 2

    JOHN FISCHER

    $67,826.33 · 44 txns

  3. 3

    PAUL DERAMO

    $62,264.64 · 81 txns

  4. 4

    Lehigh Valley

    $60,000.00 · 1 txns

  5. 5

    HARRISON M COTLER

    $56,911.61 · 64 txns

MIMEDX Group, Inc.

  1. 1

    CATO LAURENCIN

    $355,912.60 · 30 txns

  2. 2

    INOVA FAIRFAX HOSPITAL

    $351,600.00 · 50 txns

  3. 3

    PHYLLIS I GARDNER

    $319,668.75 · 4 txns

  4. 4

    MEGAN OLTMANN

    $84,040.95 · 63 txns

  5. 5

    ADVENTHEALTH ORLANDO

    $64,800.00 · 51 txns

Summary Comparison

Metric Integra LifeSciences Corporation MIMEDX Group, Inc.
Total Payments $3.4M $3.4M
% of Industry Total 0.0% 0.0%
Transaction Count 18,806 12,164
Avg per Transaction $180.65 $276.92
Recipient Count 18,727 12,157
Avg per Recipient $181.42 $277.08
Payment Type Count 7 4
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.